The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Current and emerging biomarkers in breast cancer: prognosis and prediction
Open accessAbstract
Breast cancer treatment has experienced several changes in the past decades due to the discovery of specific prognostic and predictive biomarkers that enable the application of more individualized therapies to different molecular subgroups. These subgroups show specific differences regarding biological clinical behavior. In addition to the classical clinical prognostic factors of breast cancer, established molecular biomarkers such as estrogen receptor and progesterone receptor have played a significant role in the selection of patients benefiting from endocrine therapy for many years. More recently, the human epidermal growth factor receptor 2 (HER2) has been validated to be not only a prognostic factor, but also a predictor of response to HER2 targeting therapy. The shift toward an earlier diagnosis of breast cancer due to improved imaging methods and screening programs highlights the need for new factors and combinations of biomarkers to quantify the residual risk of patients and to indicate the potential value of additional treatment strategies. The marker of proliferation Ki67 has recently emerged as an important marker due to several applications in neoadjuvant therapy in addition to its moderate prognostic value. With the introduction of high-throughput technologies, numerous multigene signatures have been identified that aim to outperform traditional markers: current prospective clinical trials are seeking evidence for their definitive role in breast cancer. There exist many more factors and approaches that have the potential to become relevant in the near future including the detection of single disseminating and circulating tumor cells in blood and bone marrow as well as of circulating cell-free DNA and microRNA. Careful randomized prospective testing and comparison with existing established factors will be required to select those emerging markers that offer substantial cost-effective benefit and thereby justify their routine use for breast cancer therapy decision-making.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Home visits: a strategy to improve newborn survival - Authors' reply
(2008) · Americanae (AECID Library) · doi:10.1016/s0140 · Cited by 22,524
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
(2023) · doi:10.1126/science · Cited by 6,063
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Algebraic decay in hierarchical graphs
Garcia, A., Sonnino, G., Malek-Mansour, M.-A., & Baras, F. (1997) · doi:10.1023/a · Cited by 5,187
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Self-citationHammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Self-citationTamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
MicroRNA Gene Expression Deregulation in Human Breast Cancer
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1783 · Cited by 4,053
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., Talantov, D., Timmermans, M., Meijer-van Gelder, M. E., Yu, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17947-1 · Cited by 2,846
Gerdes, J., Schwab, U., Lemke, H., & Stein, H. (1983) · International Journal of Cancer · doi:10.1002/ijc.2910310104 · Cited by 2,788
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Cheang, M. C. U., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P. S., Parker, J. S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp082 · Cited by 2,249
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J., Nordgren, H., Farmer, P., Praz, V., Haibe-Kains, B., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj052 · Cited by 2,063
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-18-asocco · Cited by 1,816
Self-citationSmith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60028-2 · Cited by 1,507
Self-citationGene-Expression Signatures in Breast Cancer
Sotiriou, C., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,485
Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp322 · Cited by 1,374
Buyse, M., Loi, S., van't Veer, L., Viale, G., Delorenzi, M., Glas, A. M., Saghatchian d'Assignies, M., Bergh, J., Lidereau, R., Ellis, P., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj329 · Cited by 1,238
Human Estrogen Receptor β-Gene Structure, Chromosomal Localization, and Expression Pattern1
Enmark, E., Pelto-Huikko, M., Grandien, K., Lagercrantz, S., Lagercrantz, J., Fried, G., Nordenskjöld, M., & Gustafsson, J.-A. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4470 · Cited by 1,074
D-type cyclin-dependent kinase activity in mammalian cells.
Matsushime, H., Quelle, D. E., Shurtleff, S. A., Shibuya, M., Sherr, C. J., & Kato, J. Y. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.2066 · Cited by 1,064
Formation and Activation of a Cyclin E-cdk2 Complex During the G 1 Phase of the Human Cell Cycle
Koff, A., Giordano, A., Desai, D., Yamashita, K., Harper, J. W., Elledge, S., Nishimoto, T., Morgan, D. O., Franza, B. R., & Roberts, J. M. (1992) · Science · doi:10.1126/science.1388288 · Cited by 1,043
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pandey, A., & Chinnaiyan, A. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401994101 · Cited by 1,019
c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301802 · Cited by 961
de Azambuja, E., Cardoso, F., de Castro, G., Colozza, M., Mano, M. S., Durbecq, V, Sotiriou, C., Larsimont, D., Piccart-Gebhart, M. J., & Paesmans, M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603756 · Cited by 959
Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X., Ramon y Cajal, S., Arribas, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk134 · Cited by 895
Proliferation Marker Ki-67 in Early Breast Cancer
Urruticoechea, A., Smith, I. E., & Dowsett, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.501 · Cited by 837
Self-citationLoi, S., Haibe-Kains, B., Desmedt, C., Lallemand, F., Tutt, A. M., Gillet, C., Ellis, P., Harris, A., Bergh, J., Foekens, J. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1522 · Cited by 837
Estrogen Signaling: A Subtle Balance Between ER and ER
Matthews, J. (2003) · Molecular Interventions · doi:10.1124/mi.3.5.281 · Cited by 806
Reporting Recommendations for Tumor Marker Prognostic Studies
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.0454 · Cited by 779
Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
Hayes, D. F., Bast, R. C., Desch, C. E., Fritsche, H., Kemeny, N. E., Jessup, J. M., Locker, G. Y., Macdonald, J. S., Mennel, R. G., Norton, L., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.20.1456 · Cited by 748
Dowsett, M., Cuzick, J., Wale, C., Forbes, J., Mallon, E. A., Salter, J., Quinn, E., Dunbier, A., Baum, M., Buzdar, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4798 · Cited by 724
Self-citationCDK-Independent Activation of Estrogen Receptor by Cyclin D1
Zwijsen, R. M. L., Wientjens, E., Klompmaker, R., van der Sman, J., Bernards, R., & Michalides, R. J. A. M. (1997) · Cell · doi:10.1016/s0092-8674(00)81879-6 · Cited by 720
Mattie, M. D., Benz, C. C., Bowers, J., Sensinger, K., Wong, L., Scott, G. K., Fedele, V., Ginzinger, D. G., Getts, R. C., & Haqq, C. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-24 · Cited by 715
Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer
Heneghan, H. M., Miller, N., Lowery, A. J., Sweeney, K. J., Newell, J., & Kerin, M. J. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181cc939f · Cited by 687
Expression and amplification of cyclin genes in human breast cancer.
Buckley, M. F., Sweeney, K. J. E., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicholson, R. I., DeFazio, A., Watts, C. K. W., Musgrove, E. A., & Sutherland, R. L. (1993) · PubMed · Cited by 667
Dowsett, M., Smith, I. E., Ebbs, S. R., Dixon, J. M., Skene, A., A'Hern, R., Salter, J., Detre, S., Hills, M., & Walsh, G. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djk020 · Cited by 665
Self-citationGillett, C., Fantl, V., Smith, D., Fisher, C., Bartek, J. J., Dickson, C., Barnes, D. M., & Peters, G. (1994) · PubMed · Cited by 661
Mechanisms of tamoxifen resistance
Ring, A., & Dowsett, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00776 · Cited by 651
Self-citationSmith, B., Selby, P., Southgate, J., Pittman, K., Bradley, C., & Blair, G. E. (1991) · The Lancet · doi:10.1016/0140-6736(91)92100-g · Cited by 629
Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials
Sparano, J. A., & Paik, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.1068 · Cited by 617
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
Hayes, D. F., Thor, A. D., Dressler, L. G., Weaver, D., Edgerton, S., Cowan, D., Broadwater, G., Goldstein, L. J., Martino, S., Ingle, J. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071167 · Cited by 608
Human Estrogen Receptor -Gene Structure, Chromosomal Localization, and Expression Pattern
Enmark, E. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.12.4258 · Cited by 585
Cyclin E and Survival in Patients with Breast Cancer
Keyomarsi, K., Tucker, S. L., Buchholz, T. A., Callister, M., Ding, Y., Hortobagyi, G. N., Bedrosian, I., Knickerbocker, C., Toyofuku, W., Lowe, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021153 · Cited by 557
Hartmann, L., Ingle, J. N., Wold, L. E., Gh, F., Grill, J. P., Su, J. Q., Maihle, N. J., Krook, J. E., Witzig, T. E., & Roche, P. (1979) · Open access LMU (Ludwid Maxmilian's Universitat Munchen) · doi:10.1002/1097-0142 · Cited by 556
Heterogeneity of kinase inhibitor resistance mechanisms in GIST
Liegl, B., Kepten, I., Le, C., Zhu, M., Demetri, G., Heinrich, M., Fletcher, C., Corless, C., & Fletcher, J. (2008) · The Journal of Pathology · doi:10.1002/path.2382 · Cited by 536
Ström, A., Hartman, J., Foster, J. S., Kietz, S., Wimalasena, J., & Gustafsson, J.-Å. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308319100 · Cited by 534
(2019) · Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) · doi:10.1200/jco · Cited by 522
Redundant cyclin overexpression and gene amplification in breast cancer cells.
Keyomarsi, K., & Pardee, A. B. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.3.1112 · Cited by 512
INFECTIOUS COMPLICATIONS IN PATIENTS WITH ACUTE PROMYELOCITIC LEUKEMIA TREATED WITH THE AIDA REGIMEN
C, G., M, B., La Tagliata, R., Spadea, A., D'Andrea, M., P, M., Lo‐Coco, F., Gentile, G., Micozzi, A., Alimena, G., et al. (2003) · IRIS Research product catalog (Sapienza University of Rome) · doi:10.1038/sj · Cited by 510
Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.
Roger, P., Sahla, M. E., Mäkelä, S., Gustafsson, J. A., Baldet, P., & Rochefort, H. (2001) · PubMed · Cited by 471
Viale, G., Regan, M. M., Maiorano, E., Mastropasqua, M. G., Dell'Orto, P., Rasmussen, B. B., Raffoul, J., Neven, P., Orosz, Z., Braye, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9453 · Cited by 452
Dowsett, M., Allred, C., Knox, J., Quinn, E., Salter, J., Wale, C., Cuzick, J., Houghton, J., Williams, N., Mallon, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9437 · Cited by 450
Self-citationStuart-Harris, R., Caldas, C., Pinder, S. E., & Pharoah, P. (2008) · The Breast · doi:10.1016/j.breast.2008.02.002 · Cited by 431
HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer
Paik, S., Kim, C., & Wolmark, N. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0801440 · Cited by 426
Loss of ERβ expression as a common step in estrogen-dependent tumor progression
Bardin, A., Boulle, N., Lazennec, G., Vignon, F., & Pujol, P. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00800 · Cited by 417
Estrogen Receptor Mutations in Human Disease
Herynk, M. H., & Fuqua, S. A. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0010 · Cited by 400
Howell, A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)74803-0 · Cited by 398
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer
Holst, F., Stahl, P. R., Ruiz, C., Hellwinkel, O., Jehan, Z., Wendland, M., Lebeau, A., Terracciano, L., Al-Kuraya, K., Jänicke, F., et al. (2007) · Nature Genetics · doi:10.1038/ng2006 · Cited by 375
Gennari, A., Sormani, M. P., Pronzato, P., Puntoni, M., Colozza, M., Pfeffer, U., & Bruzzi, P. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm252 · Cited by 371
Mass, R. D., Press, M. F., Anderson, S., Cobleigh, M. A., Vogel, C. L., Dybdal, N., Leiberman, G., & Slamon, D. J. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.n.026 · Cited by 359
Colleoni, M., Viale, G., Zahrieh, D., Pruneri, G., Gentilini, O., Veronesi, P., Gelber, R. D., Curigliano, G., Torrisi, R., Luini, A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0380 · Cited by 353
Dowsett, M., Smith, I. E., Ebbs, S. R., Dixon, J. M., Skene, A., Griffith, C., Boeddinghaus, I., Salter, J., Detre, S., Hills, M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.951s.11.2 · Cited by 348
Self-citationCyclin E, a Potential Prognostic Marker in Breast Cancer.
Keyomarsi, K. (1997) · doi:10.21236/ada341275 · Cited by 344
Cyclin D1 and prognosis in human breast cancer
Gillett, C., Smith, P., Gregory, W., Richards, M., Millis, R., Peters, G., & Barnes, D. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960422)69:2<92::aid-ijc4>3.0.co;2-q · Cited by 327
Elledge, R. M., Green, S., Pugh, R., Allred, D. C., Clark, G. M., Hill, J., Ravdin, P., Martino, S., & Osborne, C. K. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000320)89:2<111::aid-ijc2>3.0.co;2-w · Cited by 325
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
Jones, R. L., Salter, J., A’Hern, R., Nerurkar, A., Parton, M., Reis-Filho, J. S., Smith, I. E., & Dowsett, M. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0081-7 · Cited by 321
Self-citationMa, X.-J., Salunga, R., Dahiya, S., Wang, W., Carney, E., Durbecq, V., Harris, A., Goss, P., Sotiriou, C., Erlander, M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5026 · Cited by 315
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome
Faneyte, I. F., Schrama, J. G., Peterse, J. L., Remijnse, P. L., Rodenhuis, S., & van de Vijver, M. J. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600749 · Cited by 307
Musgrove, E. A., Hamilton, J. A., Lee, C. S., Sweeney, K. J., Watts, C. K., & Sutherland, R. L. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.6.3577 · Cited by 297
Dowsett, M., Ebbs, S. R., Dixon, J. M., Skene, A., Griffith, C., Boeddinghaus, I., Salter, J., Detre, S., Hills, M., Ashley, S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.559 · Cited by 288
Self-citationAltered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis.
Leygue, E., Dotzlaw, H., Watson, P. H., & Murphy, L. C. (1998) · PubMed · Cited by 281
Järvinen, T. A. H., Pelto-Huikko, M., Holli, K., & Isola, J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64702-5 · Cited by 277
Cyclin D1, EMS1 and 11q13 Amplification in Breast Cancer
Ormandy, C. J., Musgrove, E. A., Hui, R., Daly, R. J., & Sutherland, R. L. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1023033708204 · Cited by 270
TAILORx: Trial Assigning Individualized Options for Treatment (Rx)
Sparano, J. A. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.051 · Cited by 262
Ring, A. E., Smith, I. E., Ashley, S., Fulford, L. G., & Lakhani, S. R. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602235 · Cited by 262
Dowsett, M., Cuzick, J., Wale, C., Howell, T., Houghton, J., & Baum, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.4829 · Cited by 260
Self-citationThe HOXB13:IL17BR Expression Index Is a Prognostic Factor in Early-Stage Breast Cancer
Ma, X.-J., Hilsenbeck, S. G., Wang, W., Ding, L., Sgroi, D. C., Bender, R. A., Osborne, C. K., Allred, D. C., & Erlander, M. G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6944 · Cited by 252
Induction of Mammary Gland Hyperplasia and Carcinomas in Transgenic Mice Expressing Human Cyclin E
Bortner, D. M., & Rosenberg, M. P. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.1.453 · Cited by 245
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial
Bogaerts, J., Cardoso, F., Buyse, M., Braga, S., Loi, S., Harrison, J. A., Bines, J., Mook, S., Decker, N., Ravdin, P., et al. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0591 · Cited by 237
Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients.
Speirs, V., Malone, C. M., Walton, D. S., Kerin, M. J., & Atkin, S. L. (1999) · PubMed · Cited by 237
Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation
Anido, J., Scaltriti, M., Bech Serra, J. J., Josefat, B. S., Rojo Todo, F., Baselga, J., & Arribas, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601191 · Cited by 231
Pegram, M. D., Konecny, G., & Slamon, D. J. (2000) · Cancer Treatment and Research · doi:10.1007/978-1-4757-3147-7_4 · Cited by 222
Kohler, C., Radpour, R., Barekati, Z., Asadollahi, R., Bitzer, J., Wight, E., Bürki, N., Diesch, C., Holzgreve, W., & Zhong, X. Y. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-105 · Cited by 215
Skliris, G. P., Munot, K., Bell, S. M., Carder, P. J., Lane, S., Horgan, K., Lansdown, M. R., Parkes, A. T., Hanby, A. M., Markham, A. F., et al. (2003) · The Journal of Pathology · doi:10.1002/path.1436 · Cited by 202
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer
Board, R. E., Wardley, A. M., Dixon, J. M., Armstrong, A. C., Howell, S., Renshaw, L., Donald, E., Greystoke, A., Ranson, M., Hughes, A., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0747-9 · Cited by 201
Low Levels of Estrogen Receptor β Protein Predict Resistance to Tamoxifen Therapy in Breast Cancer
Hopp, T. A., Weiss, H. L., Parra, I. S., Cui, Y., Osborne, C. K., & Fuqua, S. A. W. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1114 · Cited by 197
Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes
Lopez, F., Belloc, F., Lacombe, F., Dumain, P., Reiffers, J., Bernard, P., & Boisseau, M. R. (1991) · Cytometry · doi:10.1002/cyto.990120107 · Cited by 193
Nielsen, N., Arnerlöv, C., Emdin, S. O., & Landberg, G. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.451 · Cited by 192
Trihia, H., Murray, S., Price, K., Gelber, R. D., Golouh, R., Goldhirsch, A., Coates, A. S., Collins, J., Castiglione‐Gertsch, M., & Gusterson, B. A. (2003) · Cancer · doi:10.1002/cncr.11188 · Cited by 189
Michalides, R., Hageman, P., van Tinteren, H., Houben, L., Wientjens, E., Klompmaker, R., & Peterse, J. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.128 · Cited by 184
Dowsett, M., Procter, M., McCaskill-Stevens, W., de Azambuja, E., Dafni, U., Rueschoff, J., Jordan, B., Dolci, S., Abramovitz, M., Stoss, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7939 · Cited by 180
Self-citationNicholson, R. I., McClelland, R. A., Finlay, P., Eaton, C. L., Gullick, W. J., Dixon, A. R., Robertson, J. F. R., Blamey, R. W., & Ellis, I. O. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80215-1 · Cited by 178
Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma
Chang, J., Ormerod, M., Powles, T. J., Allred, D. C., Ashley, S. E., & Dowsett, M. (2000) · Cancer · doi:10.1002/1097-0142(20001201)89:11<2145::aid-cncr1>3.0.co;2-s · Cited by 173
Self-citationStendahl, M., Kronblad, Å., Rydén, L., Emdin, S., Bengtsson, N. O., & Landberg, G. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601831 · Cited by 169
Nitti, D., BELLUCO, C., FASSINA, A., Ninfo, V., LISE, M., MC, M., R, B., & P, D. P. (1998) · Padua Research Archive (University of Padova) · doi:10.1016/s0959-8049 · Cited by 146
Jirström, K., Stendahl, M., Rydén, L., Kronblad, Å., Bendahl, P.-O., Stål, O., Landberg, G., & Groups., T. S. S. A. S. S. B. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0746 · Cited by 134
Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer
Dowsett, M., Smith, I. E., Ebbs, S. R., Dixon, J. M., Skene, A. I., Griffith, C. D. M., Boeddinghaus, I., Salter, J., DETRE, S. I., Hills, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2127 · Cited by 131
Self-citationClinical value of the wild-type estrogen receptor β expression in breast cancer
Omoto, Y., Inoue, S., Ogawa, S., Toyama, T., Yamashita, H., Muramatsu, M., Kobayashi, S., & Iwase, H. (2001) · Cancer Letters · doi:10.1016/s0304-3835(00)00680-7 · Cited by 129
Bartlett, J. M. S., Munro, A. F., Dunn, J., McConkey, C. C., Jordan, S., Twelves, C. J., Cameron, D., Thomas, J. S. J., Campbell, F., Rea, D. W., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70006-1 · Cited by 125
Quantification of Free Circulating Tumor DNA as a Diagnostic Marker for Breast Cancer
Catarino, R., Ferreira, M. M. F., Rodrigues, H., Coelho, A., Nogal, A., de Sousa, A., & Medeiros, R. (2008) · DNA and Cell Biology · doi:10.1089/dna.2008.0744 · Cited by 124
Chang, J. C., Powles, T. J., Allred, D. C., Ashley, S. E., Makris, A., Gregory, R. K., Osborne, C. K., & Dowsett, M. (2000) · PubMed · Cited by 115
Self-citationBièche, I., Olivi, M., Noguès, C., Vidaud, M., & Lidereau, R. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600109 · Cited by 112
Fehm, T. N., Solomayer, E., Meng, S., Tucker, T. F., Lane, N., Wang, J., & Gebauer, G. (2005) · Cytotherapy · doi:10.1080/14653240510027082 · Cited by 112
The genome landscape of ERα- and ERβ-binding DNA regions
Liu, Y., Gao, H., Marstrand, T. T., Ström, A., Valen, E., Sandelin, A., Gustafsson, J.-Α., & Dahlman‐Wright, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712085105 · Cited by 110
Cyclin E, A Potential Prognostic Marker in Breast Cancer
Keyomarsi, K. (1998) · Defense Technical Information Center (DTIC) · doi:10.21236/ada368551 · Cited by 98
The Prognostic Biomarkers HOXB13, IL17BR, and CHDH Are Regulated by Estrogen in Breast Cancer
Wang, Z., Dahiya, S. M., Provencher, H. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0310 · Cited by 95
ESR1 gene amplification in breast cancer: a common phenomenon?
Reis-Filho, J. S., Drury, S., Lambros, M. B. K., Marchiò, C., Johnson, N., Natrajan, R., Salter, J., Levey, P. M., Fletcher, O., Peto, J., et al. (2008) · Nature Genetics · doi:10.1038/ng0708-809b · Cited by 85
Self-citationDesmedt, C., Giobbie‐Hurder, A., Neven, P., Paridaens, R., Christiaens, M., Smeets, A., Lallemand, F., Haibe‐Kains, B., Viale, G., Gelber, R. D., et al. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-40 · Cited by 81
Hwang, T. S., Han, H. S., Hong, Y. C., Lee, H. J., & Paik, N. S. (2003) · Pathology International · doi:10.1046/j.1440-1827.2003.01441.x · Cited by 77
Hui, R., Cornish, A. L., McClelland, R. A., Robertson, J. F. R., Blamey, R. W., Musgrove, E. A., Nicholson, R. I., & Sutherland, R. L. (1996) · PubMed · Cited by 74
Haerslev, T., Jacobsen, G. K., & Zedeler, K. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01806492 · Cited by 70
ESR1 gene amplification in breast cancer: a common phenomenon?
Brown, L. A., Hoog, J., Chin, S., et al. (2008) · Nature Genetics · doi:10.1038/ng0708-806 · Cited by 66
Park, B., Kim, K., Heo, M.-K., Ko, S. S., Lee, K. S., Hong, S. W., Yang, W., Kim, J.-H., & Kim, G. E. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1024406223619 · Cited by 63
Wangu, Q.-S., Sabourin, C. L. K., Wang, H., et al. (1996) · Carcinogenesis · doi:10.1093/carcin/17.8.1583 · Cited by 52
Wingate, H. F., Puskás, Á., Duong, M. T., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.7.8119 · Cited by 51
Cited by
Breast cancer diagnosis: Imaging techniques and biochemical markers
Jafari, S. H., Saadatpour, Z., Salmaninejad, A., Momeni, F., Mokhtari, M., Nahand, J. S., Rahmati, M., Mirzaei, H., & Kianmehr, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26379 · Cited by 410
Augoff, K., McCue, B., Plow, E. F., & Sossey-Alaoui, K. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-5 · Cited by 363
Luporsi, E., André, F., Spyratos, F., Martin, P.-M., Jacquemier, J., Penault-Llorca, F., Tubiana-Mathieu, N., Sigal-Zafrani, B., Arnould, L., Gompel, A., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1837-z · Cited by 320
Mittal, S., Kaur, H., Gautam, N., & Mantha, A. K. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.08.028 · Cited by 295
Assessing the clinical utility of cancer genomic and proteomic data across tumor types
Yuan, Y., Van Allen, E. M., Omberg, L., Wagle, N., Amin-Mansour, A., Sokolov, A., Byers, L. A., Xu, Y., Hess, K. R., Diao, L., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2940 · Cited by 280
Metadata
- Authors
- Weigel, M. T., & Dowsett, M.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2010-12
- Volume
- 17
- Issue
- 4
- Pages
- R245-R262
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2098085902
- Cited by
- 496
- References
- 128
- FWCI
- 11.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.